SOPHiA GENETICS S.A. (SOPH) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
SOPH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, SOPHiA GENETICS S.A. (SOPH) trades at a price-to-earnings ratio of -4.6x, with a stock price of $5.40 and trailing twelve-month earnings per share of $-1.14.
Compared to the Healthcare sector median P/E of 22.3x, SOPH trades at a 121% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SOPH trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SOPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SOPH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 49.7 | - | +165% | |
| $21B | 25.5Lowest | 6.01Best | +171% | |
| $176B | 26.8 | 12.67 | +7% | |
| $124B | 34.9 | - | -5% | |
| $7B | 147.0 | - | +287%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See SOPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SOPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SOPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSOPH — Frequently Asked Questions
Quick answers to the most common questions about buying SOPH stock.
Is SOPH stock overvalued or undervalued?
SOPH current P/E: -4.6x. 5-year average P/E: N/A. Percentile: N/A.
How does SOPH's valuation compare to peers?
SOPHiA GENETICS S.A. P/E of -4.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SOPH's PEG ratio?
SOPH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.